A Trinity College Dublin spin-out, Opsona Therapeutics, has received a 33m fund to aid the developemnt of one of its drugs. The drug, OPN-305, which protects the body from rejection of donor kidneys is set to undergo a Phase II clinical trial in the following months where its tolerability, efficacy and safety will be tested.
Archives
- May 2017
- September 2016
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- July 2012
- June 2012
- March 2012
- January 2012
- October 2011
- August 2011
- June 2011
- May 2011
- March 2011
- February 2011
- November 2010
- August 2010
- July 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- June 2009










